Skip to main content

Advertisement

Table 2 Relationship between TES protein expression and clinicopathological variables in 140 cases of primary GC

From: Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene

Clinicopathological variables n TESTIN cases (%) p-Value
   Positive Negative  
Age (years)     0.384
   <56 68 12 (17.5) 49 (80.3)  
   ≥56 72 17 (23.6) 55 (76.4)  
Gender     0.886
   Female 45 9 (20.0) 36 (80.0)  
   Male 95 20 (21.1) 75 (78.9)  
Tumor size (cm)     0.789
   <5 61 12 (19.7) 49 (80.3)  
   ≥5 79 17 (21.6) 62 (78.4)  
T stage     0.441
   T1 12 1 (8.3) 11 (91.7)  
   T2 17 2 (11.8) 15 (88.2)  
   T3 85 19 (22.4) 66 (77.6)  
   T4 26 7 (26.9) 19 (73.1)  
N stage     0.520
   N0 44 6 (13.6) 38 (86.4)  
   N1 42 9 (21.4) 33 (78.6)  
   N2 43 11 (25.6) 32 (74.4)  
   N3 11 3 (27.3) 8 (72.7)  
M stage     0.997
   M0 111 23 (20.7) 88 (79.3)  
   M1 29 6 (20.7) 23 (79.3)  
Clinical stage     0.686
   I 17 2 (11.8) 15 (88.2)  
   II 28 5 (17.9) 23 (82.1)  
   III 51 11 (21.6) 40 (78.4)  
   IV 44 11 (25.0) 33 (75.0)  
Differentiation     0.007*
   Well 3 2 (66.7) 1 (33.3)  
   Moderate 30 12 (40.0) 18 (60.0)  
   Poor 97 13 (13.4) 84 (86.6)  
   Undifferentiated 10 2 (20.0) 8 (80.0)  
  1. Number of cases in each group.
  2. * Statistically significant (p < 0.05).